Latest News

Filters close
access_time Embargo lifts in 2 days
Embargo will expire: 8-Jun-2020 9:00 AM EDT Released to reporters: 5-Jun-2020 1:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 8-Jun-2020 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: New test for rare disease identifies children who may benefit from simple supplement
3-Jun-2020 4:20 AM EDT
New test for rare disease identifies children who may benefit from simple supplement
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute and the Centro de Biología Molecular Severo Ochoa in Spain have created a test that determines which children with CAD deficiency—a rare metabolic disease—are likely to benefit from receiving uridine, a nutritional supplement that has dramatically improved the lives of other children with the condition. The study was published in Genetics in Medicine.

Newswise: First map of proinsulin’s “social network” reveals new drug target for type 2 diabetes
Released: 27-May-2020 8:00 AM EDT
First map of proinsulin’s “social network” reveals new drug target for type 2 diabetes
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have mapped for the first time the vast network of proteins that interact with proinsulin, the protein the body normally processes into insulin. The study, published in Diabetes, also revealed one protein—called PRDX4—that may be essential for proinsulin folding and insulin production. The research suggests that boosting PRDX4 levels may be a novel therapeutic approach to improving the health of people with diabetes.

Newswise: Scientists identify promising immunotherapy combination for pediatric brain cancer
15-May-2020 12:50 PM EDT
Scientists identify promising immunotherapy combination for pediatric brain cancer
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature Neuroscience, is expected to lead to a clinical trial to test the benefits of the treatment in patients. The findings also hold implications for other cancers that do not respond to immunotherapy.

Newswise: Scientists show MRI predicts the efficacy of a stem cell therapy for brain injury
11-May-2020 12:45 PM EDT
Scientists show MRI predicts the efficacy of a stem cell therapy for brain injury
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute and Loma Linda University Health have demonstrated the promise of applying magnetic resonance imaging (MRI) to predict the efficacy of using human neural stem cells to treat a brain injury—a first-ever “biomarker” for regenerative medicine that could help personalize stem cell treatments for neurological disorders and improve efficacy. The study was published in Cell Reports.

Newswise: Sanford Burnham Prebys to develop broad-spectrum antivirals with $10 million Department of Defense grant
8-May-2020 2:10 PM EDT
Sanford Burnham Prebys to develop broad-spectrum antivirals with $10 million Department of Defense grant
Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that Sumit Chanda, Ph.D., has received a $10.2 million, four-year grant from the Department of Defense to develop and advance broad-spectrum antivirals for respiratory diseases. The award aims to provide U.S. military forces and the nation with safe, effective and innovative therapies that combat multiple types of respiratory viruses.

Newswise:Video Embedded researchers-use-live-virus-to-identify-30-existing-drugs-that-could-treat-covid-19
VIDEO
Released: 20-Apr-2020 8:25 AM EDT
Researchers use live virus to identify 30 existing drugs that could treat COVID-19
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA have identified 30 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19. The study was placed on bioRxiv (pronounced “bio-Archive”), an open-access distribution service for preprints of life science research.

Newswise: Pancreatic cancer blocked by disrupting cellular pH balance
3-Apr-2020 1:50 PM EDT
Pancreatic cancer blocked by disrupting cellular pH balance
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys have found a new way to kill pancreatic cancer cells by disrupting their pH equilibrium. The study, published in Cancer Discovery, reports how depleting an ion transport protein lowers the pH to a point that compromises pancreatic cancer cell growth.

Newswise: Sanford Burnham Prebys Medical Discovery Institute welcomes new trustees Karen Haynes and Donald Kearns
Released: 24-Feb-2020 8:00 AM EST
Sanford Burnham Prebys Medical Discovery Institute welcomes new trustees Karen Haynes and Donald Kearns
Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute today announced that Karen Haynes, Ph.D., president emerita at California State University San Marcos, and Donald Kearns, M.D., president emeritus at Rady Children’s Hospital-San Diego, have been appointed to the Institute’s Board of Trustees.

Newswise: A deep dive into cellular aging
18-Feb-2020 5:10 PM EST
A deep dive into cellular aging
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell’s nucleus—and identified an FDA-approved drug that helped suppress the damaging effects of the condition in cells and mice. The discovery, published in Genes & Development, could lead to treatments that promote healthy aging or prevent age-associated diseases such as cancer, Alzheimer’s disease, heart disease and more.

Newswise: Prebiotics help mice fight melanoma by activating anti-tumor immunity
6-Feb-2020 4:35 PM EST
Prebiotics help mice fight melanoma by activating anti-tumor immunity
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two prebiotics, mucin and inulin, slowed the growth of melanoma in mice by boosting the immune system’s ability to fight cancer. The study, published today in Cell Reports, provides further evidence that gut microbes have a role in shaping the immune response to cancer, and supports efforts to target the gut microbiome to enhance the efficacy of cancer therapy.

Newswise: Why can’t Bertrand Might cry? Scientists offer an answer: missing water channels
13-Jan-2020 5:05 PM EST
Why can’t Bertrand Might cry? Scientists offer an answer: missing water channels
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that cells from children with NGLY1 deficiency—a rare disorder first described in 2012—lack sufficient water channel proteins called aquaporins. The discovery was published in Cell Reports and may help explain the disorder’s wide-ranging symptoms—including the inability to produce tears, seizures and developmental delays—and opens new avenues to find therapies to treat the disorder.

Newswise: Study reveals a new approach to enhancing response to immunotherapy in melanoma
3-Jan-2020 11:40 AM EST
Study reveals a new approach to enhancing response to immunotherapy in melanoma
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys have identified a new way to boost the immune system’s ability to fight cancer. The study used a mouse model to identify the importance of the Siah2 protein in the control of immune cells called T regulatory cells (Tregs), which limit the effectiveness of currently used immunotherapies. The research, which offers a new avenue to pursue immunotherapy in cases where the treatment fails, was published today in Nature Communications.

Newswise: The secret to a long life? For worms, a cellular recycling protein is key
10-Dec-2019 4:05 PM EST
The secret to a long life? For worms, a cellular recycling protein is key
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that worms live longer lives if they produce excess levels of a protein, p62, which recognizes toxic cell proteins that are tagged for destruction. The discovery, published in Nature Communications, could help uncover treatments for age-related conditions, such as Alzheimer’s disease, which are often caused by accumulation of misfolded proteins.

Newswise: One-two punch drug combination offers hope for pancreatic cancer therapy
Released: 18-Nov-2019 11:00 AM EST
One-two punch drug combination offers hope for pancreatic cancer therapy
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice—supporting the immediate evaluation of the drugs in a clinical trial. U.S. Food and Drug Administration (FDA)–approved versions of the compounds are used today to treat certain leukemias and solid tumors, including melanoma. The study was published in Nature Cell Biology.

Newswise: Sanford Burnham Prebys awarded $3.58 million NIH grant to advance potential treatment for opioid-use disorders
21-Oct-2019 1:35 PM EDT
Sanford Burnham Prebys awarded $3.58 million NIH grant to advance potential treatment for opioid-use disorders
Sanford Burnham Prebys Medical Discovery Institute

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $3.58 million grant to Sanford Burnham Prebys scientist Anthony Pinkerton, Ph.D., to advance a potential treatment for opioid-use disorders, called SBI-553.

Released: 22-Oct-2019 8:00 AM EDT
Machine Learning’s Next Frontier: Epigenetic Drug Discovery
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images—allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more. The study was published in eLife.

Newswise: New Insights Into How to Protect Premature Babies From Common Brain Disorder
8-Oct-2019 4:05 PM EDT
New Insights Into How to Protect Premature Babies From Common Brain Disorder
Sanford Burnham Prebys Medical Discovery Institute

Premature babies have delicate brain tissue that is prone to bleeding and can result in post-hemorrhagic hydrocephalus, a dangerous condition that leads to excess fluid accumulation and brain dysfunction. Now, scientists from Sanford Burnham Prebys Medical Discovery Institute have identified a new disease mechanism and potential molecular drug target that may protect premature newborns from developing the brain disorder. The study was published in Science Advances.

Newswise: $4.96 Million CIRM Grant Awarded to Sanford Burnham Prebys to Help the Tiniest Patients
Released: 19-Aug-2019 8:00 AM EDT
$4.96 Million CIRM Grant Awarded to Sanford Burnham Prebys to Help the Tiniest Patients
Sanford Burnham Prebys Medical Discovery Institute

The California Institute for Regenerative Medicine (CIRM) has awarded a $4.96 million grant to Sanford Burnham Prebys Professor Evan Y. Snyder, M.D., Ph.D. The funding will allow Snyder to complete pre-investigational new drug (IND)-enabling studies, a step toward securing U.S. Food & Drug Administration (FDA) approval of a human trial for neural stem cells as a potential treatment for newborns who experience oxygen and blood-flow deprivation during birth. Called perinatal hypoxic-ischemic brain injury (HII), the lack of oxygen and blood flow to the brain can cause cerebral palsy and other permanent neurological disorders.

Released: 14-Aug-2019 8:00 AM EDT
Sanford Burnham Prebys expands collaboration with Lilly to investigate immunological therapies
Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute today announced a three-year extension to its existing collaboration with Eli Lilly and Company (Lilly) to discover and develop immunological therapies. The goals of the agreement are to advance ongoing projects—including a Phase 1 clinical trial of an immune therapy that arose from the research collaboration—and to expand the previous scope to include omics-based target identification studies.

Newswise: Functional Hair Follicles Grown from Stem Cells
25-Jun-2019 2:00 PM EDT
Functional Hair Follicles Grown from Stem Cells
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys have created natural-looking hair that grows through the skin using human induced pluripotent stem cells (iPSCs), a major scientific achievement that could revolutionize the hair growth industry. The findings were presented today at the annual meeting of the International Society for Stem Cell Research (ISSCR) and received a Merit Award. A newly formed company, Stemson Therapeutics, has licensed the technology.

Newswise: Nutritional Cues Regulate Pancreatic Tumor’s “Cell Drinking”
20-Jun-2019 4:55 PM EDT
Nutritional Cues Regulate Pancreatic Tumor’s “Cell Drinking”
Sanford Burnham Prebys Medical Discovery Institute

Desperate for nutrients, rapidly growing pancreatic tumors resort to scavenging “fuel” through an alternative supply route, called macropinocytosis. Blocking this process, often described as “cellular drinking,” could lead to tumor-starving drugs. Now, scientists from Sanford Burnham Prebys have identified a signaling pathway that regulates macropinocytosis, the nutritional cue that triggers the process and key metabolic differences between tumors—revealing new directions for drug development and patient treatment. The findings were published in Developmental Cell.

Newswise: ALS research reveals new treatment approach
Released: 23-May-2019 5:05 PM EDT
ALS research reveals new treatment approach
Sanford Burnham Prebys Medical Discovery Institute

New research on amyotrophic lateral sclerosis (AML) has revealed that a protein called membralin plays a key role in the disease process. The study, published in Journal of Clinical Investigation, suggests that membralin-boosting gene therapy is a potential therapeutic direction to treat this often deadly disease.

Newswise: Potential Targeted Treatment for Acute Myeloid Leukemia Identified
Released: 15-May-2019 8:00 AM EDT
Potential Targeted Treatment for Acute Myeloid Leukemia Identified
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys have shown that a protein called BMI1 is a promising drug target for an AML subtype in which two normally separate genes, CALM and AF10, fuse together. The findings, published in Experimental Hematology, provide a rationale for evaluating a BMl1-inhibiting drug that is currently in clinical development for solid tumors.

Newswise: Conquering Cancer’s Infamous KRAS Mutation
Released: 14-May-2019 8:00 AM EDT
Conquering Cancer’s Infamous KRAS Mutation
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys and PHusis Therapeutics have shown that a compound called PHT-7.3 shrinks KRAS-driven tumors in mice. In contrast to directly targeting mutant KRAS, the potential drug candidate targets the protein’s partner in crime: the cellular scaffold to which mutated KRAS attaches. The study was published in Cancer Research.

Newswise: Boosting Muscle Stem Cells to Treat Muscular Dystrophy and Aging Muscles
16-Apr-2019 12:05 PM EDT
Boosting Muscle Stem Cells to Treat Muscular Dystrophy and Aging Muscles
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys have uncovered a molecular signaling pathway involving Stat3 and Fam3a proteins that regulates how muscle stem cells decide whether to self-renew or differentiate—an insight that could lead to muscle-boosting therapeutics for muscular dystrophies or age-related muscle decline. The study was published in Nature Communications.

Newswise: New Metascape platform enables biologists to unlock big-data insights
Released: 3-Apr-2019 12:05 PM EDT
New Metascape platform enables biologists to unlock big-data insights
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys and the Genomics Institute of the Novartis Research Foundation have revealed an open-access, web-based portal that integrates more than 40 advanced bioinformatics data sources to allow non-technical users to generate insights in one click. Called Metascape, this tool removes data analysis barriers—allowing researchers to spend more time on important biological questions and less time building and troubleshooting a data analysis workflow. The platform was described today in Nature Communications.

Newswise: Gut Microbiome Directs the Immune System to Fight Cancer
28-Mar-2019 1:05 PM EDT
Gut Microbiome Directs the Immune System to Fight Cancer
Sanford Burnham Prebys Medical Discovery Institute

A study from Sanford Burnham Prebys has demonstrated a causal link between the gut microbiome and the immune system’s ability to fight cancer. The researchers identified a cocktail of 11 bacterial strains that activated the immune system and slowed the growth of melanoma in mice. The study also points to the role of unfolded protein response (UPR), a cellular signaling pathway that maintains protein health (homeostasis). Reduced UPR was seen in melanoma patients who are responsive to immune checkpoint therapy, revealing potential markers for patient stratification. The study was published in Nature Communications.

Newswise: Helping Infants Survive Brain Cancer
Released: 27-Mar-2019 8:00 AM EDT
Helping Infants Survive Brain Cancer
Sanford Burnham Prebys Medical Discovery Institute

Choroid plexus carcinoma (CPC) is a particularly challenging type of brain cancer. The tumor most commonly arises in infants under the age of one—who are too young to undergo radiation treatment. Only 40 percent of children remain alive five years after diagnosis, and those who do survive often suffer devastating long-term damage from the treatment. Progress in developing effective therapies has been hindered by the lack of models that could help researchers better understand the cancer. Now, scientists from Sanford Burnham Prebys have developed a novel mouse model of CPC and have used it to identify multiple potential drug compounds with biological activity that may be therapeutically useful. The study was published in Cancer Research.

Released: 21-Mar-2019 1:00 PM EDT
WARF Therapeutics Announces Partnership with Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute

As part of its strategic initiative to bring new pharmaceuticals closer to patients, WARF Therapeutics announces a new partnership with Sanford Burnham Prebys Medical Discovery Institute (SBP). Under the terms of the 5-year agreement, WARF and UW–Madison scientists will work with scientists at SBP’s Prebys Center to transition clinically relevant targets to early-stage drug discovery.

Newswise: Sanford Burnham Prebys Medical Discovery Institute welcomes new trustees
Released: 7-Mar-2019 8:00 AM EST
Sanford Burnham Prebys Medical Discovery Institute welcomes new trustees
Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute (SBP) today announced that Matt Browne, a partner in Cooley LLP’s San Diego office; and David L. Szekeres, senior vice president, Business Development, and general counsel for Heron Therapeutics, Inc., have been appointed to the Institute’s Board of Trustees.

27-Feb-2019 2:30 PM EST
How Prostate Cancer Becomes Treatment Resistant
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified how prostate cancer transforms into a deadly treatment-resistant subtype following treatment with anti-androgen therapy. Their findings—which include the metabolic rewiring and the epigenetic alteration that drives this switch— reveal that an FDA-approved drug holds potential as a NEPC treatment. The research also uncovers new therapeutic avenues that could prevent this transformation from occurring. The study was published in Cancer Cell.

Newswise: Targeted treatment shrinks deadly pediatric brain tumors
Released: 23-Jan-2019 8:00 AM EST
Targeted treatment shrinks deadly pediatric brain tumors
Sanford Burnham Prebys Medical Discovery Institute

For children—whose tiny bodies are still growing—chemotherapy and radiation treatments can cause lifelong damage. Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have reported that a targeted therapy that blocks a protein called LSD1 was able to shrink tumors in mice with a form of pediatric brain cancer known as medulloblastoma. LSD1 inhibitors are currently under evaluation in clinical trials for other cancers. The study was published in Nature Communications.

Newswise: Muscle Stem Cells Can Drive Cancer That Arises in Duchenne Muscular Dystrophy
Released: 15-Jan-2019 8:00 AM EST
Muscle Stem Cells Can Drive Cancer That Arises in Duchenne Muscular Dystrophy
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have demonstrated that muscle stem cells may give rise to rhabdomyosarcoma that occurs during DMD—and identified two genes linked to the tumor’s growth. The research, performed using a mouse model of severe DMD, helps scientists better understand how rhabdomyosarcoma develops in DMD—and indicates that ongoing efforts to develop treatments that stimulate muscle stem cells should consider potential cancer risk. The study was published today in Cell Reports.

Newswise: Epigenetic change causes fruit fly babies to inherit diet-induced heart disease
Released: 14-Jan-2019 5:00 PM EST
Epigenetic change causes fruit fly babies to inherit diet-induced heart disease
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified an epigenetic marker and two genes that caused heart failure in the children and grandchildren of fruit flies with high-fat-diet-induced heart dysfunction. Reversing the epigenetic modification or over-expressing the two genes protected subsequent generations from the negative heart effects of their parents’ diet. These findings help explain how obesity-related heart failure is inherited and uncover potential targets for treatment. The study was published in Nature Communications on January 14, 2019.

Newswise: Powerful microscope captures first image of “haystack” nanoscaffold that promotes cell movement
Released: 11-Jan-2019 8:00 AM EST
Powerful microscope captures first image of “haystack” nanoscaffold that promotes cell movement
Sanford Burnham Prebys Medical Discovery Institute

Using one of the most powerful microscopes in the world, scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) and University of North Carolina at Chapel Hill (UNC-Chapel Hill) have identified a dense, dynamic and disorganized actin filament nanoscaffold—resembling a haystack—that is induced in response to a molecular signal. This is the first time researchers have directly visualized, at the molecular level, a structure that is triggered in response to a cellular signal—a key finding that expands our understanding of how cells move. The study was published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

6-Dec-2018 12:00 PM EST
Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with clinicians from Scripps Clinic, have identified that the loss of two genes drives the formation of serrated colorectal cancer—yielding potential biomarkers. The research has also identified a combination treatment that has treated the cancer in mice. The study published today in Immunity.

Newswise:Video Embedded never-before-seen-dna-recombination-in-the-brain-linked-to-alzheimer’s-disease
VIDEO
20-Nov-2018 2:00 PM EST
Never-before-seen DNA recombination in the brain linked to Alzheimer’s disease
Sanford Burnham Prebys Medical Discovery Institute

Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer’s disease brains. The study, published today in Nature, reveals for the first time how the Alzheimer’s-linked gene, APP, is recombined by using the same type of enzyme found in HIV.

Newswise: Immune therapy developed through Sanford Burnham Prebys and Lilly collaboration enters Phase 1 clinical trial
Released: 15-Nov-2018 8:00 AM EST
Immune therapy developed through Sanford Burnham Prebys and Lilly collaboration enters Phase 1 clinical trial
Sanford Burnham Prebys Medical Discovery Institute

SBP today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating an inflammation-inhibiting biologic that arose from a research collaboration between Eli Lilly and Company (Lilly) and SBP formed in 2015.

Newswise: Path to Deadly Sepsis Varies by Bacterial Infection
8-Oct-2018 11:00 PM EDT
Path to Deadly Sepsis Varies by Bacterial Infection
Sanford Burnham Prebys Medical Discovery Institute

Sepsis remains a common and deadly condition that occurs when the body reacts to an infection in the bloodstream. However, scientists know little about the early stages of the condition. Now, researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC Santa Barbara have discovered that host responses during sepsis progression can vary in important ways based on pathogen type—which could lead to more effective treatments. The study published today in Cell Host and Microbe.

Newswise: Solving a medical mystery: Cause of rare type of dwarfism discovered
3-Oct-2018 1:35 PM EDT
Solving a medical mystery: Cause of rare type of dwarfism discovered
Sanford Burnham Prebys Medical Discovery Institute

For children born with Saul-Wilson syndrome, and their parents, much of their lives are spent searching for answers. First defined in 1990, only 14 cases are known worldwide. Today, these individuals have answers. A study published today in the American Journal of Human Genetics, has uncovered the cause of Saul-Wilson syndrome.

Newswise: Trustees of Sanford Burnham Prebys Medical Discovery Institute Elect New Board Leadership, Welcome New Board Member
Released: 28-Sep-2018 11:00 AM EDT
Trustees of Sanford Burnham Prebys Medical Discovery Institute Elect New Board Leadership, Welcome New Board Member
Sanford Burnham Prebys Medical Discovery Institute

Trustees of Sanford Burnham Prebys Medical Discovery Institute elect new Board leadership, welcome new Board member

Newswise: Thousands of Previously Unknown DNA Changes in the Developing Brain Revealed by Machine Learning
22-Sep-2018 2:50 PM EDT
Thousands of Previously Unknown DNA Changes in the Developing Brain Revealed by Machine Learning
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have developed new single-cell approaches wedded to machine learning. This has revealed thousands of previously unknown DNA changes arising during prenatal life in the developing mouse brain. The study published today in PNAS.

Newswise: Mannose’s Unexpected Effects on the Microbiome and Weight Gain
Released: 18-Sep-2018 11:00 AM EDT
Mannose’s Unexpected Effects on the Microbiome and Weight Gain
Sanford Burnham Prebys Medical Discovery Institute

Scientists continue to unravel links between body weight and the gut microbiome. Now, researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP) report an unexpected finding: mice fed a fatty diet and mannose, a sugar, were protected from weight gain, leaner and more fit—and this effect tracked with changes in the gut microbiome. The study published today in Cell Reports.

Newswise: Solving the Gut Inflammation Puzzle
17-Sep-2018 3:30 PM EDT
Solving the Gut Inflammation Puzzle
Sanford Burnham Prebys Medical Discovery Institute

Inflammatory bowel disease (IBD), an umbrella term for a number of gut disorders—including ulcerative colitis and Crohn’s disease—remains a clinical challenge. Now, researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with scientists at Technion – Israel Institute of Technology, have identified a protein that drives intestinal inflammation. This finding highlights new opportunities for creating targeted therapeutics. The study published today in Cell Reports.

Newswise: Malicious Brain Cell Identified
Released: 13-Sep-2018 1:00 PM EDT
Malicious Brain Cell Identified
Sanford Burnham Prebys Medical Discovery Institute

Astrocytes' important role in brain function suggests they are also involved in disease. Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified an astrocyte subpopulation as the dominant cell type to spring into action in vivo (in a living organism) in a neuroinflammatory disease setting. The study published today in eNeuro.

Newswise: An Old Drug Finds New Purpose Against Retinal Neovascularization
Released: 12-Sep-2018 2:00 PM EDT
An Old Drug Finds New Purpose Against Retinal Neovascularization
Sanford Burnham Prebys Medical Discovery Institute

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have found that the anti-malaria drug amodiaquine inhibits the apelin receptor protein, which helps drive the vascularization behind diabetic retinopathy, wet age-related macular degeneration (AMD) and other conditions. Because the drug has been approved to treat malaria for decades, it could move relatively quickly through the pipeline to help patients. The study was published in the journal PLOS ONE.

Newswise: Shedding Light on 100-Year-Old Cancer Mystery
11-Sep-2018 12:00 PM EDT
Shedding Light on 100-Year-Old Cancer Mystery
Sanford Burnham Prebys Medical Discovery Institute

Using genetic and pharmacological means, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) were surprised to find that blocking LDHA had only a limited impact on melanoma cells, since they were able to redirect energy production. Their results identify an alternative growth pathway driven by a molecule called ATF4, revealing new potential targets for drug development. The study was published today in EMBO Journal.

Newswise: Sarcolipin Tricks Muscle Cells into Using More Energy, Burning Fat
10-Sep-2018 2:50 PM EDT
Sarcolipin Tricks Muscle Cells into Using More Energy, Burning Fat
Sanford Burnham Prebys Medical Discovery Institute

Ever wonder why you burn fat and heat up when you exercise or shiver? Now, researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that sarcolipin, a small peptide only found in muscles, increases muscle energy expenditure and fat oxidization. The study was published today in the journal Cell Reports.

Newswise: Duchenne Muscular Dystrophy: How Muscle Cells Journey to the Dark Side
Released: 11-Sep-2018 8:00 AM EDT
Duchenne Muscular Dystrophy: How Muscle Cells Journey to the Dark Side
Sanford Burnham Prebys Medical Discovery Institute

Answers to treating muscular dystrophies could lie in better understanding muscle repair—which resembles a delicate cellular dance choreographed by special cells called fibro-adipogenic progenitors (FAPs). Researchers already know these cells have a dark side—they are also responsible for the muscle wasting and scarring that occurs during Duchenne muscular dystrophy (DMD). Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have revealed that FAPs don’t have just one identity—but several distinct identities that emerge during key stages of muscle regeneration. Importantly, the FAPs that drive the symptoms of DMD have defined markers, meaning they could be targeted for drug development. The study was published in Nature Communications.


Showing results

150 of 354

close
0.46482